We recommend you to use analysis of PDL BioPharma Inc fundamentals to see if markets are today mispricing the firm. We found thirty-seven available financial ratios for PDL BioPharma Inc which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma Inc fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Please also confirm PDL BioPharma Inc Price to Earning to check out the company can sustain itself for few more years.Use PDL BioPharma to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of PDL BioPharma to be traded at $3.07 in 30 days
PDL BioPharma Inc Valuation Over Time
PDL BioPharma Company SummaryPDL BioPharma competes with NantKwest, Del Mar, Dimension Therapeutics, Denali Therapeutics, and VBI Vaccines. PDL BioPharma Inc is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies methods for humanizing antibodies polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. PDL BioPharma Inc. has license agreements with various biotechnology and pharmaceutical companies as well as acquires royalty and other assets. PDL BioPharma Inc was formerly known as Protein Design Labs Inc. and changed its name to PDL BioPharma Inc. in 2006. PDL BioPharma Inc. was founded in 1986 and is headquartered in Incline Village Nevada.
PDL BioPharma Cash Flow from Operations vs Current Ratio
PDL BioPharma Inc is considered to be number one stock in cash flow from operations category among related companies. It is rated below average in current ratio category among related companies . The ratio of Cash Flow from Operations to Current Ratio for PDL BioPharma Inc is about 23,329,114